Pharming Group convenes the Annual General Meeting of Shareholders 2023
Corporate updatesPharming Group N.V. announces that the Company’s 2023 Annual General Meeting of Shareholders (AGM) will be held on Wednesday, May 17, 2023, at 14:00 CEST.
Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS
Corporate updatesPharming Group N.V. announces that the US Food and Drug Administration (FDA) has approved Joenja® (leniolisib) for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. Joenja®, an oral, selective PI3Kδ inhibitor, is the first and only treatment approved in the US for APDS, a rare and progressive primary immunodeficiency.
Pharming Group: all proposals Annual General Meeting of Shareholders approved
Corporate updatesPharming Group N.V. announces that at its Annual General Meeting of shareholders (AGM), held today, all proposals were approved.
Pharming announces the filing of its 2021 Annual Report, with Form 20-F also filed with the U.S. Securities and Exchange Commission and convenes its 2022 AGM
Corporate updatesPharming announces the filing of its Annual Report for the year ended 31 December 2021. The Company has also filed its Form 20-F with the U.S. Securities and Exchange Commission (SEC) for the same period. In addition, the company convenes its 2022 AGM.
Pharming Group Notice of 2021 Full Year Results
Corporate updatesPharming confirms it will announce its preliminary (unaudited) financial report for the full year 2021 on Thursday, March 17, 2022